A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer - Concepedia

Concepedia

Publication | Open Access

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

DOI Full Paper Access

45

Citations

41

References

2024

Year

Tanya B. Dorff, Lisa G. Horvath, Karen A. Autio, Alice Bernard‐Tessier, Matthew B. Rettig, Jean‐Pascal Machiels, Mehmet Asım Bilen, Martijn P. Lolkema, Nabil Adra, Sylvie Rottey,

Clinical Cancer Research

Abstract

Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.

References

	Year	Citations

Page 1